Abstract
The past few decades have seen alarming rates of antimicrobial drug resistance. This trend paralleled a lack of conventional methods of discovery of antibiotics with novel mechanisms of action. Although use of mammalian models remains indispensable for preclinical testing of new antimicrobial compounds, combating emerging multidrug-resistant microbial pathogens may require the use of robust, high-throughput experimental systems that can accelerate drug development. The recent discovery of striking similarities in innate immune signaling pathways between Drosophila melanogaster and mammals has led to a surge in the use of this minihost as an alternative model in studying a variety of infectious diseases. Several genetic screens for microbial pathogenicity in Drosophila identified virulence traits shown to be important for infection in mammals that may serve as targets for future drug development. In addition, conventional antimicrobial agents retain full activity in D. melanogaster infection models, which may pave the way for use of this minihost for high-throughput antimicrobial drug screening. Finally, the availability of genetic tools that allow for conditional inactivation of almost every gene in D. melanogaster is anticipated to result in the discovery of novel immunomodulatory mechanisms of action of newly identified antimicrobial compounds. Overall, the powerful genetics of and capacity for large-scale screening in D. melanogaster make this minihost a promising complementary model that may result in a new paradigm in antimicrobial drug discovery. However, antimicrobial drug discovery in such heterologous, phylogenetically disparate minihosts as the fruit flies, would still require further validation in mammalian models.
Keywords: Drosophila melanogaster, antimicrobials, mini-host models, drug discovery, high-throughput screening, melanogaster, indispensable, immunocompromised, pathogenicity, phylogenetically, transcriptomes, peptidoglycan, metchnikowin, drosomycin, diptericin, attacin, cecropin, inoculum, Aspergillus, siderophore
Current Pharmaceutical Design
Title: Drosophila melanogaster As a Model Host for the Study of Microbial Pathogenicity And the Discovery of Novel Antimicrobial Compounds
Volume: 17 Issue: 13
Author(s): Georgios Chamilos, George Samonis and Dimitrios P. Kontoyiannis
Affiliation:
Keywords: Drosophila melanogaster, antimicrobials, mini-host models, drug discovery, high-throughput screening, melanogaster, indispensable, immunocompromised, pathogenicity, phylogenetically, transcriptomes, peptidoglycan, metchnikowin, drosomycin, diptericin, attacin, cecropin, inoculum, Aspergillus, siderophore
Abstract: The past few decades have seen alarming rates of antimicrobial drug resistance. This trend paralleled a lack of conventional methods of discovery of antibiotics with novel mechanisms of action. Although use of mammalian models remains indispensable for preclinical testing of new antimicrobial compounds, combating emerging multidrug-resistant microbial pathogens may require the use of robust, high-throughput experimental systems that can accelerate drug development. The recent discovery of striking similarities in innate immune signaling pathways between Drosophila melanogaster and mammals has led to a surge in the use of this minihost as an alternative model in studying a variety of infectious diseases. Several genetic screens for microbial pathogenicity in Drosophila identified virulence traits shown to be important for infection in mammals that may serve as targets for future drug development. In addition, conventional antimicrobial agents retain full activity in D. melanogaster infection models, which may pave the way for use of this minihost for high-throughput antimicrobial drug screening. Finally, the availability of genetic tools that allow for conditional inactivation of almost every gene in D. melanogaster is anticipated to result in the discovery of novel immunomodulatory mechanisms of action of newly identified antimicrobial compounds. Overall, the powerful genetics of and capacity for large-scale screening in D. melanogaster make this minihost a promising complementary model that may result in a new paradigm in antimicrobial drug discovery. However, antimicrobial drug discovery in such heterologous, phylogenetically disparate minihosts as the fruit flies, would still require further validation in mammalian models.
Export Options
About this article
Cite this article as:
Chamilos Georgios, Samonis George and P. Kontoyiannis Dimitrios, Drosophila melanogaster As a Model Host for the Study of Microbial Pathogenicity And the Discovery of Novel Antimicrobial Compounds, Current Pharmaceutical Design 2011; 17 (13) . https://dx.doi.org/10.2174/138161211795703744
DOI https://dx.doi.org/10.2174/138161211795703744 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bone Disruption and Environmental Pollutants
Endocrine, Metabolic & Immune Disorders - Drug Targets Does Intra-Articular Injection of Platelet-Rich Plasma Have an Effect on Cartilage Thickness in Patients with Primary Knee Osteoarthritis?
Current Rheumatology Reviews Transcriptional Analysis of JAK/STAT Signaling in Glioblastoma Multiforme
Current Pharmacogenomics and Personalized Medicine Changes in the Peripheral Endocannabinoid System as a Risk Factor for the Development of Eating Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets Influence of Toll-Like-Receptor Ligands on the Dendritic Cell - T Cell Interactions: Therapeutic Options for Allergic Diseases? Mini-Review
Inflammation & Allergy - Drug Targets (Discontinued) MEET THE GUEST EDITOR
Combinatorial Chemistry & High Throughput Screening Current and Future Clinical Strategies in Colon Cancer Prevention and the Emerging Role of Chemoprevention
Current Pharmaceutical Design Oncogene-Directed Therapies as Modulators of Cancer Coagulopathy, Angiogenesis and Tumor-Vascular Interface
Current Signal Transduction Therapy Editorial [Hot Topic: Latest Developments in Pharmaceutical Design of Arachidonic Acid Metabolites: Prostaglandins, Thromboxanes, Hepoxilins and Isoprostanes (Executive Editors: J.-M. Dogne and K.-H. Ruan )]
Current Pharmaceutical Design GAMESS As a Free Quantum-Mechanical Platform for Drug Research
Current Topics in Medicinal Chemistry Influence of β-D-mannuronic Acid, as a New Member of Non-steroidal Anti- Inflammatory Drugs Family, on the Expression Pattern of Chemokines and their Receptors in Rheumatoid Arthritis
Current Drug Discovery Technologies p38 MAP Kinase Mediated Proteoglycan Synthesis as a Target for the Prevention of Atherosclerosis
Cardiovascular & Hematological Disorders-Drug Targets Innovative Treatment Approach for Cancer-Related Cachexia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Angiogenesis and AngiomiRs in Non-Hodgkin´s Lymphomas
Current Angiogenesis (Discontinued) Alternative Polyadenylation and Its Impact on Cellular Processes
MicroRNA The Role of CTLA-4 Gene Polymorphisms in Autoimmune Disease Pathogenesis: A 2012 Update
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Cardiovascular Proteomics
Current Proteomics Preface
Current Pharmaceutical Design Overview of Current Immunotherapies Targeting Mutated KRAS Cancers
Current Topics in Medicinal Chemistry Gastric Mucosal Protection And Central Nervous System
Current Pharmaceutical Design